{"result": {"id": "90ed7a12-a07a-4e3d-a8fa-e5a672fb6b99", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>山楂<|>organization<|>中药成分之一，用于红曲与中药复合制剂中)\n##\n(\"entity\"<|>泽泻<|>organization<|>中药成分之一，用于红曲与中药复合制剂中)\n##\n(\"entity\"<|>白术<|>organization<|>中药成分之一，用于红曲与中药复合制剂中)\n##\n(\"entity\"<|>非诺贝特片<|>organization<|>贝特类药物，剂量为0.1 g，3次/d)\n##\n(\"entity\"<|>微粒化非诺贝特<|>organization<|>贝特类药物，剂量为0.2 g，1次/d)\n##\n(\"entity\"<|>非诺贝特缓释胶囊<|>organization<|>贝特类药物，剂量为0.25 g，1次/d)\n##\n(\"entity\"<|>苯扎贝特<|>organization<|>贝特类药物，剂量为0.2 g，3次/d)\n##\n(\"entity\"<|>苯扎贝特缓释片<|>organization<|>贝特类药物，剂量为0.4 g，1次/d)\n##\n(\"entity\"<|>吉非贝齐<|>organization<|>贝特类药物，剂量为0.6 g，2次/d)\n##\n(\"entity\"<|>IPE<|>organization<|>ω-3脂肪酸类药物)\n##\n(\"entity\"<|>EPA+DHA<|>organization<|>ω-3脂肪酸类药物，剂量为1~4 g/d)\n##\n(\"entity\"<|>烟酸缓释片<|>organization<|>烟酸及其同类物，剂量为0.375~1.000 g，1次/d)\n##\n(\"relationship\"<|>山楂<|>红曲与中药复合制剂<|>山楂是红曲与中药复合制剂的成分之一<|>8)\n##\n(\"relationship\"<|>泽泻<|>红曲与中药复合制剂<|>泽泻是红曲与中药复合制剂的成分之一<|>8)\n##\n(\"relationship\"<|>白术<|>红曲与中药复合制剂<|>白术是红曲与中药复合制剂的成分之一<|>8)\n##\n(\"relationship\"<|>非诺贝特片<|>贝特类药物<|>非诺贝特片属于贝特类药物<|>9)\n##\n(\"relationship\"<|>微粒化非诺贝特<|>贝特类药物<|>微粒化非诺贝特属于贝特类药物<|>9)\n##\n(\"relationship\"<|>非诺贝特缓释胶囊<|>贝特类药物<|>非诺贝特缓释胶囊属于贝特类药物<|>9)\n##\n(\"relationship\"<|>苯扎贝特<|>贝特类药物<|>苯扎贝特属于贝特类药物<|>9)\n##\n(\"relationship\"<|>苯扎贝特缓释片<|>贝特类药物<|>苯扎贝特缓释片属于贝特类药物<|>9)\n##\n(\"relationship\"<|>吉非贝齐<|>贝特类药物<|>吉非贝齐属于贝特类药物<|>9)\n##\n(\"relationship\"<|>IPE<|>ω-3脂肪酸<|>IPE属于ω-3脂肪酸类药物<|>9)\n##\n(\"relationship\"<|>EPA+DHA<|>ω-3脂肪酸<|>EPA+DHA属于ω-3脂肪酸类药物<|>9)\n##\n(\"relationship\"<|>烟酸缓释片<|>烟酸及其同类物<|>烟酸缓释片属于烟酸及其同类物<|>9)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752165911, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 819, "prompt_tokens": 3491, "total_tokens": 4310, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 3392}, "prompt_cache_hit_tokens": 3392, "prompt_cache_miss_tokens": 99}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 是一种红曲与中药（山楂、泽 泻、白术）的复合制剂，具有降低胆固醇的作用。\n4.2    主要降 TG 药物\n　　主要降 TG 的药物包括贝特类药物、ω-3 脂肪酸、 烟酸及其同类物（表 4）。\n\n\n\n4.1.2   胆固醇吸收抑制剂包括依折麦布和海博麦布。二 者均为口服用药，常规用法均为 10 mg， 1 次 /d。与他 汀类药物联用时，依折麦布可使 LDL-C 水平进一步降 低 18%~20%［21］，海博麦布进一步降低 16% 左右［22］。 胆固醇吸收抑制剂不良反应轻微，且多为一过性，主要 表现为头痛和消化道症状。也应关注其与他汀类药物联 用时，可发生肝酶增高和肌痛等不良反应，禁用于妊娠 期和哺乳期。\n4.1.3   PCSK9 抑制剂，目前获批上市的有依洛尤单抗、 阿利西尤单抗、托莱西单抗及小干扰 RNA 英克司兰。 依洛尤单抗 140 mg 或阿利西尤单抗 75 mg，每 2 周 1 次 皮下注射，安全性和耐受性好，可使 LDL-C 水平明显降 低达 50%~70%，其严重不良事件、肌肉相关事件、新 发糖尿病、出血性卒中和神经认知事件等不良反应发生 率与安慰剂相似［23］ 。托莱西单抗 150 mg，每 2 周 1 次 皮下注射，LDL-C 降幅类似［24］ 。英克司兰降 LDL-C 的幅度与 PCSK9 单抗近似，但作用更持久，注射 1 剂 疗效可维持半年［25］。常见不良反应包括注射部位疼痛 或肿块、疲劳感、恶心以及肌肉疼痛等。\n4.1.4   普罗布考有抗氧化和延缓动脉粥样硬化作用。目 前主要联合其他降脂药物用于治疗家族性高胆固醇血症 患者， 以减轻皮肤黄色瘤的发生及严重程度。成年人常\n\n\n表 4    主要降 TG 药物\nTable 4    Main TG-lowering drugs\n药物 分类\t常用药物\t剂量\t不良反应\n\n\n贝特类\t非诺贝特片\t0.1 g，3 次 /d\t\n\t微粒化非诺贝特\t0.2 g，1 次 /d\t\n\t非诺贝特缓释胶囊\t0.25 g，1 次 /d\t包括肝脏、肌肉和肾\n\t苯扎贝特\t0.2 g，3 次 /d\t毒性等\n\t苯扎贝特缓释片\t0.4 g，1 次 /d\t\n\t吉非贝齐\t0.6 g，2 次 /d\t\n　ω - 3 脂肪酸\tIPE\nEPA+DHA\t1~4 g/d\t　胃肠道反应，大剂量 可能增加轻微出血、 新发心房颤动风险\n　烟酸及 其同类 物\t烟酸缓释片\t0.375~1.000 g，\n1 次 /d\t颜面潮红、皮肤�\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>红曲与中药复合制剂<|>organization<|>一种红曲与中药（山楂、泽泻、白术）的复合制剂，具有降低胆固醇的作用)\n##\n(\"entity\"<|>贝特类药物<|>organization<|>主要降TG的药物，包括非诺贝特片、微粒化非诺贝特、非诺贝特缓释胶囊、苯扎贝特、苯扎贝特缓释片、吉非贝齐)\n##\n(\"entity\"<|>ω-3脂肪酸<|>organization<|>主要降TG的药物，包括IPE和EPA+DHA)\n##\n(\"entity\"<|>烟酸及其同类物<|>organization<|>主要降TG的药物，包括烟酸缓释片)\n##\n(\"entity\"<|>依折麦布<|>organization<|>胆固醇吸收抑制剂，口服用药，常规用法为10 mg，1次/d)\n##\n(\"entity\"<|>海博麦布<|>organization<|>胆固醇吸收抑制剂，口服用药，常规用法为10 mg，1次/d)\n##\n(\"entity\"<|>PCSK9抑制剂<|>organization<|>包括依洛尤单抗、阿利西尤单抗、托莱西单抗及小干扰RNA英克司兰)\n##\n(\"entity\"<|>依洛尤单抗<|>organization<|>PCSK9抑制剂，140 mg每2周1次皮下注射，安全性和耐受性好)\n##\n(\"entity\"<|>阿利西尤单抗<|>organization<|>PCSK9抑制剂，75 mg每2周1次皮下注射，安全性和耐受性好)\n##\n(\"entity\"<|>托莱西单抗<|>organization<|>PCSK9抑制剂，150 mg每2周1次皮下注射，LDL-C降幅类似)\n##\n(\"entity\"<|>英克司兰<|>organization<|>小干扰RNA，降LDL-C的幅度与PCSK9单抗近似，但作用更持久)\n##\n(\"entity\"<|>普罗布考<|>organization<|>有抗氧化和延缓动脉粥样硬化作用，主要用于治疗家族性高胆固醇血症患者)\n##\n(\"relationship\"<|>红曲与中药复合制剂<|>贝特类药物<|>Both are used for lowering cholesterol or TG levels<|>3)\n##\n(\"relationship\"<|>红曲与中药复合制剂<|>ω-3脂肪酸<|>Both are used for lowering cholesterol or TG levels<|>3)\n##\n(\"relationship\"<|>红曲与中药复合制剂<|>烟酸及其同类物<|>Both are used for lowering cholesterol or TG levels<|>3)\n##\n(\"relationship\"<|>贝特类药物<|>ω-3脂肪酸<|>Both are main TG-lowering drugs<|>5)\n##\n(\"relationship\"<|>贝特类药物<|>烟酸及其同类物<|>Both are main TG-lowering drugs<|>5)\n##\n(\"relationship\"<|>ω-3脂肪酸<|>烟酸及其同类物<|>Both are main TG-lowering drugs<|>5)\n##\n(\"relationship\"<|>依折麦布<|>海博麦布<|>Both are cholesterol absorption inhibitors<|>7)\n##\n(\"relationship\"<|>依洛尤单抗<|>阿利西尤单抗<|>Both are PCSK9 inhibitors<|>7)\n##\n(\"relationship\"<|>依洛尤单抗<|>托莱西单抗<|>Both are PCSK9 inhibitors<|>7)\n##\n(\"relationship\"<|>依洛尤单抗<|>英克司兰<|>Both are PCSK9 inhibitors<|>7)\n##\n(\"relationship\"<|>阿利西尤单抗<|>托莱西单抗<|>Both are PCSK9 inhibitors<|>7)\n##\n(\"relationship\"<|>阿利西尤单抗<|>英克司兰<|>Both are PCSK9 inhibitors<|>7)\n##\n(\"relationship\"<|>托莱西单抗<|>英克司兰<|>Both are PCSK9 inhibitors<|>7)\n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_eca0c75fdd229eee653be13d5e2909e5f7b05aa2648de9b71cea6efdffc049b4_v2"}